Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connections™ Coffee Talk: How to Best Apply PARP Inhibition Strategies in Patient Care

Release Date: May 31, 2019
Expiration Date: May 31, 2020
Media: Internet - based

Activity Overview

Information pertaining to the applications of poly(ADP-ribose) polymerase (PARP) inhibitor therapy continues to emerge at a rapid pace, with multiple PARP inhibitors approved for the treatment of patients with germline BRCA-mutated, HER2-negative breast cancer. This engaging, interactive, online educational activity is designed to solidify your understanding of the mechanistic rationale for the use of these medications and help you optimize their use in your clinic, including mitigation of potential treatment-related adverse events associated with these agents. Additionally, it will raise your awareness of investigational approaches utilizing PARP inhibitors. Through a series of cases, descriptive text, expert video interview video clips, and self-assessment questions, the expert activity faculty panel addresses multiple clinical challenges and key topics pertaining to the use of PARP inhibitors.

CME Activity Table of Contents

  • Pre-Activity Questions
  • Hot Topic 1: The Current State of PARP Inhibitors in Breast Cancer
  • Hot Topic 2: Verdicts on Patient Management Approaches to Set Expectations and Mitigate Adverse Events
  • Hot Topic 3: Understanding the Implications of Genetic Assessment for Therapeutic Selection of PARP Inhibition
  • Hot Topic 4: How Might PARP Inhibition Strategies Be Expanded in the Future?
  • Postactivity Questions

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Explain the mechanistic rationale for the use of PARP inhibition in the treatment of patients with breast cancer
  • Outline key safety and efficacy data from studies of PARP inhibition in the management of patients with breast cancer
  • Apply recent clinical data to the development of plans to mitigate adverse events associated with PARP inhibitor therapy
  • Summarize key ongoing studies that are exploring PARP inhibitor monotherapy and combinations in different settings for patients with breast cancer

Faculty, Staff, and Planners’ Disclosures

Sara A. Hurvitz
Sara A. Hurvitz, MD
Associate Professor of Medicine, Division of Hematology/Oncology
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica–UCLA Outpatient Hematology/Oncology Practice
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosures: Consultant: Ambryx, Amgen, Bayer, Boehringer Ingelheim Pharma, BioMarin, Cascadian, Daiichi Sankyo, Dignitana, Genentech, GlaxoSmithKline, Lilly, MacroGenics, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris, Puma, Roche, Seattle Genetics; Other: Travel – Lilly, Novartis, OBI Pharma.

Jennifer K. Litton
Jennifer K. Litton, MD
Associate Professor
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Genentech, EMD Serono, Pfizer, Zenith, AstraZeneca; Consultant: AstraZeneca, Pfizer (uncompensated); Speakers Bureau: PER®, MedLearning.

Mark E. Robson
Mark E. Robson, MD
Chief, Breast Medicine Service
Attending Physician
Breast Medicine Service and Clinical Genetic Services
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Disclosures: Grant/Research Support: AbbVie, AstraZeneca, Medivation, Pfizer, Tesaro, Myriad, Invitae; Consultant: AstraZeneca, McKesson, Merck (uncompensated); Other: Travel - AstraZeneca.

Nadine M. Tung
Nadine M. Tung, MD
Associate Professor
Harvard Medical School
Director, Cancer Genetics and Prevention Program
Beth Israel Deaconess Medical Center
Boston, MA

Disclosures: Grant/Research Support: AstraZeneca.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By